Coldstream Capital Management’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Coldstream Capital Management's MRNA Position: Q2 2026 in Review
Coldstream Capital Management increased its Moderna (MRNA) stake by 4.5% in Q2 2026, buying an estimated $20.7K and bringing the position to 9,260 shares worth $648K. The position accounts for 0.01% of the portfolio, ranked #632.
Coldstream Capital Management first reported a position in MRNA in Q2 2021 and has held it in 19 quarters since. The position peaked at $750K in Q4 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Coldstream Capital Management held 9,260 shares of Moderna worth $648K as of Q2 2026.
- Coldstream Capital Management bought 401 Moderna shares in Q2 2026, an estimated $20.7K.
- Moderna made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #632 holding.
- Coldstream Capital Management first reported a position in Moderna in Q2 2021 and has held it in 19 quarters since.
- Coldstream Capital Management's Moderna position peaked at $750K in Q4 2022.
- 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.